The attempt to conflate utterly different things i
Post# of 72440
(Total Views: 304)
Posted On: 04/25/2019 9:55:45 AM
The attempt to conflate utterly different things is very telling.
Breakthrough designation is not an FDA judgment on efficacy of a Phase 2 clinical trial. To claim that "the FDA does not think" that it was efficacious, as two of the multi-identities say, is incorrect. This is not a judgment as to efficacy or of the success of a clinical trial.
Something can be tremendously successful without getting breakthrough designation, which is given under certain conditions that involve subjective judgment by a bureaucrat.
The FACTS are that Brilacidin-OM was stunningly effective for the dose of cisplatin that is usually given. No amount of dodging that alters the FACTS.
Brilacidin-OM was the FIRST treatment to prevent oral mucositis and when it did not prevent it, it reduced the severity and duration.
Look at the links I posted. Those are actual facts, not just calumnies from people with ill intent toward this company.
Breakthrough designation is not an FDA judgment on efficacy of a Phase 2 clinical trial. To claim that "the FDA does not think" that it was efficacious, as two of the multi-identities say, is incorrect. This is not a judgment as to efficacy or of the success of a clinical trial.
Something can be tremendously successful without getting breakthrough designation, which is given under certain conditions that involve subjective judgment by a bureaucrat.
The FACTS are that Brilacidin-OM was stunningly effective for the dose of cisplatin that is usually given. No amount of dodging that alters the FACTS.
Brilacidin-OM was the FIRST treatment to prevent oral mucositis and when it did not prevent it, it reduced the severity and duration.
Look at the links I posted. Those are actual facts, not just calumnies from people with ill intent toward this company.
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼